Molecular analysis of an HBsAg-negative hepatitis B virus mutant selected in a tenofovir-treated HIV-hepatitis B virus co-infected patient

AIDS

Volumn 23, Issue 2, 2009, Pages 268-272

  Amini Bavil Olyaee, Samad ^a   Sheldon, Julie ^b   Lutz, Thomas ^c   Trautwein, Christian ^a   Tacke, Frank ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c Infektiologikum   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DNA DIRECTED DNA POLYMERASE ALPHA; EFAVIRENZ; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; ANAMNESIS; ANTIVIRAL RESISTANCE; ARTICLE; CASE REPORT; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MALE; MIXED INFECTION; MOLECULAR BIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; SEQUENCE ANALYSIS; STOP CODON; VIRUS MUTANT; VIRUS REPLICATION;

ADENINE; ADULT; ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; GENE PRODUCTS, POL; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; MUTATION; PHOSPHONIC ACIDS; VIRUS REPLICATION;

EID: 58849151844     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283224316     Document Type: Article

References (18)

1. Soriano V, Puoti M, Peters M, Benhamou Y, Sulkowski M, Zoulim F, et al. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS 2008; 22:1399-1410.
2. Tacke F, Manns MP, Trautwein C. Influence of mutations in the Hepatitis B Virus genome on virus replication and drug resistance: implications for novel antiviral strategies. Curr Med Chem 2004; 11:2667-2777.
3. Sheldon J, Camino N, Rodes B, Bartholomeusz A, Kuiper M, Tacke F, et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 2005; 10:727-734.
4. Henke-Gendo C, Amini-Bavil-Olyaee S, Challapalli D, Trautwein C, Deppe H, Schulz TF, et al. Symptomatic Hepatitis B reactivation despite reduced viral fitness is associated with HBV test and immune escape mutations in an HIV-coinfected patient. J Infect Dis 2008; 198:1620-1624.
5. Tacke F, Gehrke C, Luedde T, Heim A, Manns MP, Trautwein C. Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of lamivudine- resistant mutants. J Virol 2004; 78:8524-8535.
6. Tacke F, Liedtke C, Bocklage S, Manns MP, Trautwein C. CREB/ PKA sensitive signalling pathways activate and maintain expression levels of the hepatitis B virus pre-S2/S promoter. Gut 2005; 54:1309-1317.
7. Tacke F, Amini-Bavil-Olyaee S, Heim A, Luedde T, Manns MP, Trautwein C. Acute hepatitis B virus infection by genotype F despite successful vaccination in an immune-competent German patient. J Clin Virol 2007; 38:353-357.
8. Baldick CJ, Tenney DJ, Mazzucco CE, Eggers BJ, Rose RE, Pokornowski KA, et al. Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance. Hepatology 2008; 47:1473-1482.
9. Chen RY, Edwards R, Shaw T, Colledge D, Delaney WE, Isom H, et al. Effect of the G1896A precore mutation on drug sensitivity and replication yield of Iamivudine-resistant HBV in vitro. Hepatology 2003; 37:27-35.
10. Jeong JK, Yoon GS, Ryu WS. Evidence that the 5′-end cap structure is essential for encapsidation of hepatitis B virus pregenomic RNA. J Virol 2000; 74:5502-5508.
11. Guidotti LG, Matzke B, Pasquinelli C, Shoenberger JM, Rogler CE, Chisari FV. The hepatitis B virus (HBV) precore protein inhibits HBV replication in transgenic mice. J Virol 1996; 70:7056-7061.
12. Parekh S, Zoulim F, Ahn SH, Tsai A, Li J, Kawai S, et al. Genome replication, virion secretion, and e antigen expression of naturally occurring hepatitis B virus core promoter mutants. J Virol 2003; 77:6601-6612.
13. Quiros-Roldan E, Calabresi A, Lapadula G, Tirelli V, Costarelli S, Cologni G, et al. Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV. Antivir Ther 2008; 13:341- 348.
14. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007; 45:1056-1075.
15. Mauss S, Wedemeyer H. Treatment of chronic hepatitis B and the implications of viral resistance to therapy. Expert Rev Anti Infect Ther 2008; 6:191-199.
16. Yang H, Westland CE, Delaney WE, Heathcote EJ, Ho V, Fry J, et al. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 2002; 36:464-473.
17. Seigneres B, Pichoud C, Ahmed SS, Hantz O, Trepo C, ZouIim F. Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B. J Infect Dis 2000; 181:1221-1233.
18. Wakil SM, Kazim SN, Khan LA, Raisuddin S, Parvez MK, Cuptan RC, et al. Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus. J Med Virol 2002; 68:311-318.